What is Leerink Partnrs’ Forecast for Arvinas Q1 Earnings?

Arvinas, Inc. (NASDAQ:ARVN) – Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Arvinas in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of ($0.50) per share for the quarter. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. Leerink Partnrs also issued estimates for Arvinas’ Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.79) EPS, FY2025 earnings at ($2.89) EPS and FY2026 earnings at ($3.53) EPS.

Several other equities research analysts have also recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a research note on Friday. BMO Capital Markets reduced their price objective on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. Guggenheim reaffirmed a “buy” rating on shares of Arvinas in a research note on Thursday, December 12th. Oppenheimer reduced their price target on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Finally, Barclays lowered their price objective on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, Arvinas presently has a consensus rating of “Moderate Buy” and an average price target of $61.45.

Arvinas Stock Performance

ARVN stock opened at $18.97 on Monday. Arvinas has a one year low of $16.61 and a one year high of $53.08. The firm has a market cap of $1.30 billion, a PE ratio of -4.06 and a beta of 1.88. The firm’s 50 day moving average price is $19.46 and its 200-day moving average price is $23.44.

Hedge Funds Weigh In On Arvinas

Institutional investors have recently modified their holdings of the business. Braidwell LP increased its holdings in shares of Arvinas by 148.3% in the 3rd quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock valued at $31,637,000 after acquiring an additional 767,242 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in Arvinas during the third quarter worth approximately $9,989,000. JPMorgan Chase & Co. boosted its holdings in Arvinas by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock valued at $57,371,000 after purchasing an additional 367,343 shares in the last quarter. FMR LLC raised its holdings in Arvinas by 7.6% during the third quarter. FMR LLC now owns 2,883,604 shares of the company’s stock worth $71,023,000 after purchasing an additional 204,317 shares in the last quarter. Finally, Wasatch Advisors LP raised its holdings in Arvinas by 58.3% during the third quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock worth $10,737,000 after purchasing an additional 160,510 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.